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b-thalassemia, a hereditary blood disorder caused by defective synthe-sis of hemoglobin b globin chains, leads to ineffective erythropoiesis
and chronic anemia that may require blood transfusions. Sotatercept
(ACE-011) acts as a ligand trap to inhibit negative regulators of late-stage
erythropoiesis in the transforming growth factor b superfamily, correcting
ineffective erythropoiesis. In this phase II, open-label, dose-finding study, 16
patients with transfusion-dependent b-thalassemia and 30 patients with
non-transfusion-dependent b-thalassemia were enrolled at seven centers in
four countries between November 2012 and November 2014. Patients were
treated with sotatercept at doses of 0.1, 0.3, 0.5, 0.75, or 1.0 mg/kg to deter-
mine a safe and effective dose. Doses were administered by subcutaneous
injection every 3 weeks. Patients were treated for ≤22 months. Response
was assessed as a ≥20% reduction in transfusion burden sustained for 24
weeks in transfusion-dependent b-thalassemia patients, and an increase in
hemoglobin level of ≥1.0 g/dL sustained for 12 weeks in non-transfusion-
dependent b-thalassemia patients. Sotatercept was well tolerated. After a
median treatment duration of 14.4 months (range 0.6-35.9), no severe life-
threatening adverse events were observed. Thirteen percent of patients
reported serious but manageable adverse events. The active dose of sotater-
cept was ≥0.3 mg/kg for patients with non-transfusion-dependent b-tha-
lassemia and ≥0.5 mg/kg for those with transfusion-dependent b-tha-
lassemia. Of 30 non-transfusion-dependent b-thalassemia patients treated
with ≥0.1 mg/kg sotatercept, 18 (60%) achieved a mean hemoglobin
increase ≥1.0 g/dL, and 11 (37%) an increase ≥1.5 g/dL, sustained for ≥12
weeks. Four (100%) transfusion-dependent b-thalassemia patients treated
with 1.0 mg/kg sotatercept achieved a transfusion-burden reduction of
≥20%. Sotatercept was effective and well tolerated in patients with b-tha-
lassemia. Most patients with non-transfusion-dependent b-thalassemia
treated with higher doses achieved sustained increases in hemoglobin level.
Transfusion-dependent b-thalassemia patients treated with higher doses of
sotatercept achieved notable reductions in transfusion requirements. This
trial was registered at ClinicalTrials.gov with the number NCT01571635.
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ABSTRACT
Introduction
b-thalassemia is a hereditary blood disorder caused by
defective synthesis of the b globin chains of hemoglobin1
characterized by ineffective erythropoiesis.2-4 Mutations in
the b-globin genes lead to reduced or absent b-globin
chain synthesis, increasing the ratio of α-globin to non-α-
globin chains. Due to the relative excess of α-globin
chains, α-globin precipitates within erythroblasts as
hemichromes, leading to oxidative stress, maturation
arrest, membrane damage and apoptosis of late-stage ery-
throid precursors, and reduced red blood cell (RBC) life
span.4-6 Although erythropoiesis-stimulating agents have
been used in patients with b-thalassemia, ineffective ery-
thropoiesis is not corrected.7 Use of erythropoiesis-stimu-
lating agents is, therefore, not recommended for the treat-
ment of b-thalassemia.7,8
b-thalassemia phenotypes vary in severity, ranging from
asymptomatic thalassemia minor to non-transfusion-
dependent thalassemia (NTDT) (including thalassemia
intermedia and hemoglobin E - b-thalassemia) to transfu-
sion-dependent thalassemia (TDT) (thalassemia major).
Treatment of TDT involves regular and lifelong blood
transfusions leading to iron overload; long-term manage-
ment of iron overload requires regular iron chelation ther-
apy.9,10 However, iron chelation therapy is associated with
significant toxicities and requires a high level of treatment
adherence and monitoring that can be difficult to manage
and may have a negative impact on patients’ quality of
life.11,12 Bone marrow transplantation offers potentially cur-
ative treatment,13 but is not possible in all patients,14 and is
associated with significant morbidity and mortality.15
Gene therapy has shown early promise but is still under
investigation.16 The treatment of NTDT is based on man-
aging the long-term complications of ineffective erythro-
poiesis, including chronic anemia and iron overload,17
using iron chelation therapy and occasional RBC transfu-
sion.18,19
Sotatercept is a ligand trap that inhibits transforming
growth factor beta (TGF-b) superfamily members includ-
ing growth differentiation factor 11 (GDF-11) and activin
B.20,21 GDF-11 is overexpressed in immature erythroblasts
in b-thalassemia.21 Aberrant GDF-11 production may
induce expansion of erythroid progenitors and increase
oxidative stress, leading to maturation arrest of late ery-
throid precursors and ineffective erythropoiesis.21
Preclinical work has shown that administration of an
activin receptor IIA (ActRIIA) ligand trap decreases GDF-
11 concentration, reduces reactive oxidative stress levels,
and promotes terminal maturation in immature erythro -
blasts.21 Sotatercept is a novel recombinant fusion protein
consisting of the extracellular domain of the human
ActRIIA (ACVR2A) linked to the human immunoglobulin
G1 Fc domain.20 When administered subcutaneously,
sotatercept increased hemoglobin levels and RBC count in
healthy, postmenopausal women.22 In a phase II trial of
patients with lower-risk myelodysplastic syndromes and
anemia, sotatercept reduced transfusion burden in 47% of
patients with a high transfusion burden, and increased
hemoglobin levels in 58% of patients with a low transfu-
sion burden.23 In a b-thalassemia mouse model, RAP-011
(a murine analog of sotatercept) improved hematologic
parameters including RBC count, total hemoglobin, hema-
tocrit, and mean corpuscular volume.21
The aim of this phase II study was to determine a safe,
tolerable, and effective dose of sotatercept to increase
hemoglobin levels and reduce blood transfusion burden in
adults with TDT and NTDT b-thalassemia.
Methods
In this phase II, open-label, dose-finding study, patients were
enrolled at seven centers in France, Greece, Italy, and the United
Kingdom (listed in the Online Supplementary Data) between
November 2012 and November 2014. The study was approved by
individual institutional review boards at participating centers and,
where appropriate, national health authorities, and was conducted
in compliance with the Declaration of Helsinki. All patients pro-
vided written informed consent. ClinicalTrials.gov registration num-
ber: NCT01571635.
Inclusion criteria
Eligible patients were aged ≥18 years with a diagnosis of TDT
or NTDT, and an Eastern Cooperative Oncology Group
Performance Status of 0 to 1. Transfusion dependence was defined
as receiving ≥2 RBC units every 30 days for ≥168 days prior to
study enrollment, with no transfusion-free period of >45 consecu-
tive days during this period. The mean hemoglobin level before
transfusion was ≤10.5 g/dL in the 168 days prior to enrollment,
with the last pretransfusion hemoglobin level preceding enroll-
ment being ≤10.5 g/dL.
Non-transfusion dependence was defined as ≤1 episode of
transfusion during the 168 days prior to enrollment; an episode of
transfusion was defined as ≤4 RBC units received during the 168
days prior to enrollment. Exclusion criteria are listed in the Online
Supplementary Data.
Study design
To determine a safe and tolerable dose of sotatercept, a dose-
escalation study was carried out. Patients were initially enrolled in
two cohorts, receiving doses of 0.1 mg/kg and 0.3 mg/kg, admin-
istered by subcutaneous injection every 3 weeks. Four dose-esca-
lation cohorts, with doses of 0.5, 0.75, 1.0, and 1.5 mg/kg, were
subsequently opened to enrollment. Details of the study design
are included in the Online Supplementary Data.
Study endpoints
Primary efficacy endpoints were a reduction in transfusion bur-
den of ≥20% from pretreatment levels, sustained for 24 weeks in
TDT patients, and an increase in hemoglobin level of ≥1.0 g/dL sus-
tained for 12 weeks from mean pretreatment hemoglobin levels in
NTDT patients. Hematologic parameters, including hemoglobin
levels and RBC counts, were measured on days 1, 8, and 15 (±3
days) of each 3-week sotatercept dose period. Secondary endpoints
included reduction in RBC transfusion burden in TDT patients,
hemoglobin level increase from baseline in NTDT patients, and
safety. Exploratory endpoints included iron metabolism markers
(including serum ferritin and hepcidin), and clinical symptoms asso-
ciated with ineffective erythropoiesis and anemia (including
extramedullary hematopoiesis, leg ulcers, and bilirubin levels).
Statistical analysis
Efficacy analyses were carried out on the intent-to-treat popula-
tion, which included all patients enrolled for treatment. Efficacy
data are presented by assigned dose group. Safety analyses were
conducted on the safety population, defined as those patients who
received one or more dose of sotatercept. Safety data are present-
ed prior to intrapatient dose escalation for sotatercept dose groups
and presented post-intrapatient dose escalation for patients over-
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all. The data cutoff date for this analysis was November 27, 2015.




As of November 27, 2015, 46 patients had been enrolled
between November 2012 and November 2014 – 16 with
TDT and 30 with NTDT (Online Supplementary Figure S1).
The patients’ baseline demographic and disease character-
istics are shown in Table 1; the data are presented by
assigned dose level of sotatercept prior to dose escalation.
All patients received two or more doses of sotatercept.
The median duration of treatment was 19.6 months
(range, 0.6-35.9) for NTDT patients and 13.8 months
(range, 1.4-27.7) for TDT patients.
Erythroid response 
Non-transfusion-dependent b-thalassemia patients
Of the 30 patients with NTDT treated with sotatercept
doses of 0.1 to 1.0 mg/kg, 18 (60%) achieved a mean
hemoglobin increase of ≥1.0 g/dL, and 11 (37%) had a
mean hemoglobin increase of ≥1.5 g/dL sustained for ≥12
weeks (Figure 1A). The highest rate of response was seen
with 0.75 mg/kg sotatercept: 86% (6 of 7) of the patients
treated with this dose achieved an increase in hemoglobin
of ≥1.5 g/dL. Responders receiving sotatercept 0.5 mg/kg
experienced the greatest maximum increase in hemoglo-
bin levels within 12 weeks versus baseline (3.2±0.2 g/dL)
(Figure 1B). No patients receiving sotatercept 0.1 mg/kg
achieved a response.
The mean change in hemoglobin levels from baseline in
NTDT patients is shown in Figure 2. No significant differ-
ences in reticulocyte count or fetal hemoglobin (HbF) lev-
els were reported for NTDT patients during the study
(data not shown). The starting active dose of sotatercept in
patients with NTDT, based on the observed responses,
was ≥0.3 mg/kg.
Of four patients with NTDT who were receiving con-
comitant hydroxyurea therapy at enrollment, three con-
tinued to receive hydroxyurea during the study (dose
range 54-84 mg/kg) without interruption or modification;
Sotatercept TGF-b ligand trap in β-thalassemia
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Table 1. Baseline characteristics of patients with non-transfusion-dependent and transfusion-dependent b-thalassemia treated with sotatercept
by assigned dose level.
Characteristic                                                                                    Sotatercept dose
                                                        0.1 mg/kg                    0.3 mg/kg                 0.5 mg/kg             0.75 mg/kg             1.0 mg/kg            Overall
                                                            (n=8)                             (n=9)                          (n=8)                      (n=12)                      (n=9)                 (N=46)
NTDT patients                                n=6                            n=6                         n=6                      n=7                      n=5                 n=30
Age, years
Median                                                          39.5                                      47.0                                  39.0                               43.0                               41.0                         42.0
Range                                                         32.0-53.0                              37.0-55.0                          34.0-54.0                      29.0-65.0                      19.0-52.0                19.0-65.0
Female, n (%)                                              3 (50)                                  3 (50)                              3 (50)                           6 (86)                           1 (20)                    16 (53)
Weight, kg                                                                                                                                                                                                                                                               
Median                                                            54.0                                      58.0                                  64.2                               56.0                               62.0                         58.9
Range                                                          48.0-85.0                              53.6-65.0                          41.0-75.0                      47.6-75.0                      56.0-67.0                41.0-85.0
Hemoglobin, g/dL
Median                                                             8.8                                        8.5                                     8.5                                 8.7                                 7.6                           8.4
Range                                                           5.9-10.7                                 6.0-9.5                              6.4-9.3                          7.1-9.6                          6.6-9.4                    5.9-10.7
Mean±SD                                                  8.6±1.68                              8.3±1.26                          8.2±1.13                       8.5±0.89                       7.7±1.04                 8.3±1.18
Mean corpuscular volume, fL
Mean                                                               76.2                                      75.6                                  75.5                               63.2                               78.6                         73.3
Median                                                           75.8                                      75.8                                  68.4                               61.1                               80.3                         72.1
Range                                                          67.7-83.8                              61.6-90.5                         62.6-103.4                     54.6-80.4                      70.6-89.3               54.6-103.4
TDT patients                                   n=2                            n=3                         n=2                      n=5                      n=4                 n=16
Age, years
Median                                                            41.5                                      34.0                                  35.0                               45.0                               39.5                         35.5
Range                                                          34.0-49.0                              23.0-39.0                          34.0-36.0                      33.0-51.0                      27.0-46.0                23.0-51.0
Female, n (%)                                              1 (50)                                  1 (33)                               0 (0)                            2 (40)                           2 (50)                     6 (38)
Weight, kg                                                                                                                                                                                                                                                               
Median                                                            49.4                                      65.7                                  70.7                               58.0                               63.0                         60.1
Range                                                          46.9-51.8                              52.0-71.0                          60.5-80.8                      48.5-83.0                      53.5-85.9                46.9-85.9
b-thalassemia major, n (%)                    2 (100)                                 1 (33)                             2 (100)                          3 (60)                          4 (100)                   12 (75)
b-thalassemia intermedia*, n (%)             0                                       2 (67)                                   0                               2 (40)                               0                          4 (25)
Transfusion burden,                                   15, 33                                14, 18, 33                            30, 30                   8, 18, 18, 30, 35             18, 18, 18, 24                    -
RBC units/24 weeks†
Hemoglobin, g/dL
Median                                                             9.5                                        8.6                                     9.8                                 8.9                                 9.6                           9.3
Range                                                            9.3-9.7                                 8.5-10.6                            9.4-10.1                        8.0-10.0                        8.6-10.9                  8.0-10.9
NTDT: non-transfusion-dependent b-thalassemia; TDT: transfusion-dependent b-thalassemia; SD: standard deviation; RBC: red blood cell. *Patients with b-thalassemia intermedia
gene mutations who met the transfusion burden requirement were classified as having TDT. †Values presented for transfusion burden for individual TDT patients.
two achieved a mean hemoglobin increase of ≥1 g/dL sus-
tained for ≥12 weeks.
Transfusion-dependent b-thalassemia patients
Of 16 patients with TDT treated with sotatercept, ten
(63%) achieved a transfusion burden reduction of ≥20%
sustained for ≥24 weeks; seven patients (44%) achieved a
reduction of ≥33%, and two patients (13%), a reduction of
≥50% (Figure 3). Five of the ten patients achieved transfu-
sion burden reduction while maintaining stable or
improved hemoglobin levels at 12 weeks. The mean
change in hemoglobin level from baseline to the end of
treatment was 0.7 g/dL in all patients with TDT. Nine
patients (56%) achieved a reduction in transfusion fre-
quency over 24 weeks, receiving fewer transfusions per 24
weeks during treatment, while maintaining stable or
improved hemoglobin levels versus pretransfusion levels.
Four patients (25%) also achieved a reduction in transfu-
sion frequency over 24 weeks; however, their hemoglobin
levels were lower than pretransfusion levels. The remain-
ing three (19%) patients (2 receiving 0.75 mg/kg sotater-
cept, 1 receiving 0.3 mg/kg sotatercept) experienced an
increase in transfusion frequency, requiring between 0.7-
1.0 additional transfusions per 24 weeks, representing an
increase of 6.7-17.2% from baseline. Based on the
observed responses, the active starting dose of sotatercept
in patients with TDT was ≥0.5 mg/kg.
Bilirubin
For NTDT patients, indirect bilirubin and total bilirubin
decreased by 5-25% for patients receiving 0.3, 0.75, and
1.0 mg/kg (Online Supplementary Figure S2A). Among TDT
patients with available bilirubin data at baseline, indirect
bilirubin and total bilirubin increased by between 15%
and 80% during treatment versus baseline at all dose levels
(Online Supplementary Figure S2B). However, the changes
were not statistically significant, and there was wide vari-
ability in the level of change.
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Figure 1. Response to sotatercept treatment in patients with non-transfusion-dependent β-thalassemia.  (A) Percentage of sotatercept-treated non-transfusion-
dependent b-thalassemia patients achieving mean hemoglobin level increases from baseline of ≥1.0 g/dL and ≥1.5 g/dL sustained for ≥12 weeks by assigned dose
group. (B) Average maximum increase in hemoglobin levels within 12 weeks versus baseline levels in responders versus non-responders by dose group. Responders
were those patients achieving a ≥1.0 g/dL increase in hemoglobin levels sustained for ≥12 weeks. Error bars show the standard deviation of the mean. Hb: hemo-
globin.
Figure 2. Mean change in hemoglo-
bin levels from baseline up to day
400 in patients with non-transfu-
sion-dependent b-thalassemia
treated with different doses of
sotatercept. Data are presented by
assigned dose level, prior to intrap-





The effect of sotatercept on extramedullary masses, as
measured by magnetic resonance imaging, was reported
for four patients with NTDT and one with TDT. The
TDT patient experienced a reduction in extramedullary
mass volume at 12 months after treatment with sotater-
cept 0.75 mg/kg (data not shown); however, due to an
unequal distribution of the mass, it was not possible to
determine the exact volume of the mass. One NTDT
patient experienced reduction in extramedullary mass vol-
ume at 12 months after treatment with sotatercept 0.3
mg/kg, with the reduction ranging from 0.4% to 59.3%
across three separate extramedullary masses (Online
Supplementary Figure S3A), alongside a stable increase in
hemoglobin level. Another NTDT patient treated with
sotatercept 1.0 mg/kg experienced volume increases of
67% and 55% in two extramedullary masses, at 7 months
after treatment (Online Supplementary Figure S3B). This cor-
related with an increase in hemoglobin levels (6 g/dL at
baseline versus 8 g/dL at 7 months after treatment). Two
NTDT patients experienced changes in volumes of
extramedullary masses of between −6.3% and +22.5% at
11 months after treatment with sotatercept 1.0 mg/kg
(data not shown).
Leg ulcers
Seven NTDT patients had a history of leg ulcers at base-
line; the effect of sotatercept on chronic leg ulcers was
reported for one NTDT patient. The chronic leg ulcers
improved, and the dischromic area was reduced following
treatment with sotatercept 0.5 mg/kg for 6 months (Online
Supplementary Figure S4).
Red blood cell morphology
Changes to RBC morphology were recorded for all
patients during the study. Representative images of the
changes observed are provided in Online Supplementary
Figure S5. Reductions in hypochromia, anisocytosis, and
poikilocytosis, and the proportion of target cells were
reported, and were associated with increased hemoglobin
levels.
Serum ferritin
Among NTDT patients who responded to sotatercept
treatment, mean levels of serum ferritin decreased regard-
less of iron chelation therapy status (Online Supplementary
Figure S6A,B). In contrast to NTDT patients, all TDT
patients received iron chelation therapy. Levels of serum
ferritin decreased over time in TDT patients (Online
Supplementary Figure S6C).
Safety
Twenty-five of 46 patients (54%) experienced one or
more treatment-related adverse events; the most common
treatment-related adverse events in all patients were bone
pain [26% (n=12)], arthralgia [15% (n=7)], back pain [11%
(n=5)], asthenia/fatigue [11% (n=5)], and hypertension
[11% (n=5)] (Table 2). Treatment-related adverse events led
to discontinuation of sotatercept in eight patients (17%)
(Table 2); of these eight patients, seven were not dependent
on transfusions and one was transfusion-dependent.
All 46 patients experienced one or more treatment-emer-
gent adverse events (Online Supplementary Table S1); six
(13%) experienced one or more serious adverse events
(Online Supplementary Table S2). Nine patients (20%) expe-
rienced one or more grade 3-4 treatment-emergent adverse
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Table 2. Incidence of treatment-related adverse events of any grade occurring in sotatercept-treated patients in any dose cohort.
Adverse events, n (%)                                                     Sotatercept dose (data presented prior to                                Overall (data presented
                                                                                                                  intrapatient dose escalation)                                         post-intrapatient dose 
                                                                              0.1 mg/kg      0.3 mg/kg         0.5 mg/kg        0.75 mg/kg       1.0 mg/kg             escalation)
                                                                                  (n=8)               (n=9)                  (n=8)                (n=12)                (n=9)                     (N=46)
Patients with ≥1 treatment-emergent AE*     8 (100)               9 (100)                   8 (100)                 12 (100)                9 (100)                      46 (100)
Patients with ≥1 treatment-related AE*                          2 (25)                 2 (22)                     4 (50)                    8 (67)                   6 (67)                        25 (54)
Bone pain                                                                                2 (25)                 2 (22)                     2 (25)                     1 (8)                    4 (44)                        12 (26)
Arthralgia                                                                                     0                           0                          1 (13)                    3 (25)                   1 (11)                         7 (15)
Back pain                                                                                     0                           0                          1 (13)                    2 (17)                   2 (22)                         5 (11)
Asthenia/fatigue                                                                         0                           0                          1 (13)                    3 (25)                   1 (11)                         5 (11)
Hypertension                                                                              0                           0                          1 (13)                    2 (17)                   1 (11)                         5 (11)
Pain in extremity                                                                        0                           0                          1 (13)                    2 (17)                        0                               3 (7)
Patients with treatment-emergent                      2 (25)                      0                          1 (13)                    3 (25)                   2 (22)                         8 (17)
AE leading to discontinuation†
Treatment-emergent AE leading 
to discontinuation‡                                                                                                                                                                                                                                       
Hypertension                                                                              0                           0                               0                         2 (17)                        0                               2 (4)
Superficial thrombophlebitis                                             1 (13)                      0                               0                              0                             0                               1 (2)
Injection site erythema                                                           0                           0                               0                          1 (8)                         0                               1 (2)
Pyrexia                                                                                          0                           0                               0                              0                        1 (11)                          1 (2)
Extramedullary hematopoiesis                                              0                           0                               0                              0                        1 (11)                          1 (2)
Ventricular extrasystoles                                                        0                           0                          1 (13)                         0                             0                               1 (2)
Hypersensitivity                                                                         0                           0                               0                          1 (8)                         0                               1 (2)
Bone pain                                                                                1 (13)                      0                               0                              0                             0                               1 (2)
Adverse events (AE) in each dose cohort are presented prior to intrapatient dose escalation. Total AE are presented after-intrapatient dose escalation. *AE occurring in ≥5% of
sotatercept-treated patients. †AE occurring in any sotatercept-treated patient. ‡One patient had both injection site erythema and hypersensitivity as AE leading to treatment dis-
continuation.
events; hypertension and anemia were the most frequent
[4% (n=2)] (Online Supplementary Table S3). The incidences
of anemia were not related to treatment with sotatercept
and anemia resolved within one treatment cycle.
The most common treatment-emergent adverse events
of any grade among the 30 NTDT patients were headache
[53% (n=16)], arthralgia [47% (n=14)], cough [40%
(n=12)], and asthenia/fatigue [37% (n=11)] (Online
Supplementary Table S4). 
The most common treatment-emergent adverse events
among the 16 TDT patients were bone pain [63% (n=10)],
back pain (56% (n=9)], asthenia/fatigue [56% (n=9)]),
headache [44% (n=7)], and arthralgia [44% (n=7]) (Online
Supplementary Table S4). Most treatment-emergent adverse
events were mild and did not lead to treatment discontin-
uation (Table 2).
Bone pain was reported equally among the different
sotatercept dose cohorts; the mean time to first onset of
bone pain was similar between dose cohorts and the dura-
tion of bone pain was short (mean 12.0 days).
Asthenia was less frequent at higher dose levels; 13% (3
incidences/23 doses received) versus 5% (4 incidences/81
doses received) for TDT patients and 36% (47 inci-
dences/132 doses received) versus 5% (3 incidences/67
doses received) for NTDT patients at 0.1 mg/kg and 1.0
mg/kg, respectively) (data not shown).
Observed differences between baseline and on-treat-
ment laboratory values for liver and kidney function,
including alanine aminotransferase, aspartate aminotrans-
ferase, and serum creatinine levels, were within the ranges
expected for this population and were not related to treat-
ment (data not shown).
Dose delays for safety reasons were reported in eight
patients, all with NTDT.
Discussion
b-thalassemia is characterized by chronic anemia due to
ineffective erythropoiesis and peripheral hemolysis. The
current treatment for TDT is demanding, requiring regular
blood transfusions and lifelong iron chelation therapy. No
standardized treatment for NTDT is available, and no
treatment is currently available to improve ineffective ery-
thropoiesis. Previous investigational treatments for NTDT
have included HbF modulators such as butyrates, azaciti-
dine, or hydroxyurea, with or without erythropoietin;
however, results with these and other modulators of HbF
have been inconsistent.24,25
Sotatercept, a recombinant fusion protein that acts as a
ligand trap for TGF-b superfamily ligands, is hypothesized
to improve late-stage erythropoiesis by reducing prolifer-
ation of early erythroid progenitors and precursors while
increasing differentiation and maturation of late-stage
RBC precursors.20,21 This drug may therefore present a
novel approach to restoring effective erythropoiesis in b-
thalassemia.
In this phase II, open-label, dose-finding study, sotater-
cept exhibited a good safety profile, and was tolerated by
most patients. The most frequent adverse events were
bone, articular or back pain, and asthenia/fatigue.
Treatment discontinuation due to adverse events was rare,
and the incidence of grade 3-4 adverse events was low.
Changes in laboratory values for liver and kidney function
were not thought to be treatment-related and were in line
with fluctuations seen in b-thalassemia patients without
treatment. The active dose of sotatercept was ≥0.3 mg/kg
for NTDT patients and ≥0.5 mg/kg for TDT patients.
Importantly, concomitant administration of hydroxyurea
did not appear to interfere with the response to sotater-
cept, or with treatment compliance.
The majority (75%) of NTDT patients treated with
higher doses (0.75-1.0 mg/kg) of sotatercept achieved sus-
tained increases in hemoglobin of ≥1.0 g/dL. Similarly,
66% of TDT patients treated with higher doses of sotater-
cept (0.75-1.0 mg/kg) achieved reductions of ≥33% in
RBC transfusion requirements. The increase in hemoglo-
bin and reduction in RBC transfusion correlated with
increased serum exposure to sotatercept (data not shown),
although responses were not proportional to sotatercept
dose because of interpatient variability in serum drug
exposure. The small number of patients in each dose
group makes comparisons between sotatercept levels dif-
ficult. Studies are ongoing to identify any differences in
baseline characteristics between responders and non-
responders.
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Figure 3. Percentages of transfu-
sion-dependent b-thalassemia
patients treated with different
doses of sotatercept who achieved
a reduction in transfusion burden
of ≥20%, ≥33%, and ≥50% sus-
tained for ≥24 weeks. 
Ineffective erythropoiesis in b-thalassemia is associated
with increased iron absorption, and patients with TDT
often require regular RBC transfusions, further increasing
the risk of iron overload. Reducing ineffective erythro-
poiesis and transfusion burden will decrease the rate of
iron loading and associated complications such as heart,
liver, and endocrine disorders. In this study, decreases in
serum ferritin levels were observed in sotatercept-treated
patients with NTDT and TDT, with the decreases occur-
ring in a dose-dependent manner, regardless of concur-
rent treatment with iron chelation therapy. Although
these results suggest that sotatercept may reduce iron
absorption by reducing ineffective erythropoiesis, other
mechanisms such as removal or redistribution of iron
from overloaded organs may also contribute to reduced
iron levels. Further studies will be required to elucidate
the mechanism of action; however, a reduction in iron
overload with long-term use may translate into improved
outcomes for patients.
Sotatercept treatment was associated with a reduction
in the volume of extramedullary masses, as measured by
magnetic resonance imaging, in two patients with record-
ed data – one with NTDT and one with TDT. However,
this change in extramedullary mass volume was not
observed for all patients, and, due to technical difficulties,
precise estimation of extramedullary mass volume was
not always possible. Reductions in the volumes of these
masses did not appear to correlate with response. Further
study is needed to determine the effect of sotatercept on
extramedullary masses. 
In rodent models, sotatercept acts on ineffective ery-
thropoiesis to reduce production of α-globin aggregates
and apoptosis of late erythroid precursors, thereby
increasing the efficiency of RBC production and hemo-
globin levels.21,26 Although hemoglobin levels increased in
NTDT patients during the study, no significant differ-
ences in HbF or reticulocyte count were reported. In a
small subset of patients, normalization of RBC morphol-
ogy was reported and associated with increasing hemo-
globin levels over time. These data suggest that sotater-
cept may increase the lifespan of RBC in part by improv-
ing reticulocyte quality. These changes are consistent
with the mode of action of sotatercept as a ligand trap for
TGF-b superfamily members, including GDF-11. Binding
of sotatercept to GDF-11 inhibits SMAD2/3 signaling,
reducing TGF-b superfamily ligand signaling and thereby
promoting terminal differentiation of erythroblasts.20
There are some limitations to this study, notably the
small number of patients enrolled, which limited the abil-
ity to draw comparisons between different sotatercept
dose groups. The inclusion of both NTDT and TDT b-
thalassemia patients also resulted in patients being
grouped into smaller subgroups that further limited the
scope of the study, especially as intrapatient dose escala-
tion was allowed. The short duration of follow-up may
be another limitation, and longer follow-up would pro-
vide information on the long-term clinical efficacy and
safety of sotatercept. 
This study demonstrated the safety and efficacy of
sotatercept in patients with b-thalassemia. An improve-
ment in hemoglobin levels and reduction in transfusion
burden with sotatercept treatment have also been
demonstrated in a phase II study of anemia patients with
lower-risk myelodysplastic syndromes.23 This suggests
that sotatercept may work to decrease ineffective ery-
thropoiesis in multiple disease states via a single underly-
ing mode of action. Preliminary data with sotatercept led
to the initiation of a similar phase II study in b-tha-
lassemia of the related recombinant fusion protein, luspa-
tercept. Luspatercept has more selective activity on GDF-
11, and is also safe and effective in the treatment of b-tha-
lassemia (Piga A, et al. manuscript submitted) and
myelodysplastic syndromes.27 Luspatercept comprises the
modified extracellular domain of human ActRIIB linked
to the human IgG Fc domain,26,28 and has a similar mode
of action to sotatercept but does not bind to other mem-
bers of the TGF-b superfamily, such as activin A.20,26 A
double-blind, randomized, placebo-controlled phase III
trial of luspatercept in patients who require regular RBC
transfusions due to b-thalassemia has recently completed
recruitment (BELIEVE; NCT02604433). Luspatercept is
also being studied in a phase III trial of patients with very
low-, low- and intermediate-risk myelodysplastic syn-
dromes (MEDALIST; NCT02631070). While the decision
was made not to advance trials of sotatercept in b-tha-
lassemia due to binding of sotatercept to activin A,
sotatercept represents the first drug developed in its class,
functioning as a TGF-b superfamily inhibitor to correct
ineffective erythropoiesis. TGF-b superfamily inhibition
may provide an alternative or complementary treatment
option for patients with b-thalassemia.
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